Multiple myeloma patients receiving large volume leukapheresis efficiently yield enough CD34+ cells to allow double transplants

Journal of Clinical Apheresis

Volumn 24, Issue 1, 2009, Pages 6-11

  Zubair, Abba C ^a   Rymer, R ^a   Young, J ^a   Keeton, U ^a   Befort, R ^b   Nolot, B ^b   Evans, C ^b   Bleach, T ^b   Torloni, A ^b  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Large volume leukapheresis; Multiple myeloma; Stem cell collection

Indexed keywords

ADULT; AGED; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLOOD VOLUME; CD34 SELECTION; CELL VOLUME; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; CRYOPRESERVATION; FEMALE; HUMAN; HUMAN CELL; INTERMETHOD COMPARISON; LARGE VOLUME LEUKAPHERESIS; LEUKAPHERESIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NEUTROPHIL; RETRANSPLANTATION; RETROSPECTIVE STUDY; TARGET CELL; TREATMENT INDICATION;

ADULT; AGED; ANTIGENS, CD34; COST-BENEFIT ANALYSIS; FEMALE; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; LEUKAPHERESIS; LEUKOCYTE COUNT; MALE; MIDDLE AGED; MULTIPLE MYELOMA; RETROSPECTIVE STUDIES; TRANSPLANTATION, AUTOLOGOUS;

EID: 63249094994     PISSN: 07332459     EISSN: 10981101     Source Type: Journal    
DOI: 10.1002/jca.20190     Document Type: Article

References (25)

1. Anderson KC, Barut BA, Ritz J, Freedman AS, Nadler LM. Autologous bone marrow transplantation therapy for multiple myeloma. Eur J Haematol Suppl 1989;51:157-163.
2. Gahrton G, Bjorkstrand B. Progress in haematopoietic stem cell transplantation for multiple myeloma. J Intern Med 2000;248: 185-201.
3. Sirohi B, Powles R, Treleaven J, Mainwaring P, Kulkarni S, Pandha H, Bhagwati N, Horton C, Shinghal S, Mehta J. The role of autologous transplantation in patients with multiple myeloma aged 65 years and over. Bone Marrow Transplant 2000;25:533-539.
4. Tosi P, Zamagni E, Ronconi S, Benni M, Motta MR, Rizzi S, Tura S, Cavo M. Safety of autologous hematopoietic stem cell transplantation in patients with multiple myeloma and chronic renal failure. Leukemia 2000;14:1310-1313.
5. Gianni AM. Where do we stand with respect to the use of peripheral blood progenitor cells? Ann Oncol 1994;5:781-784.
6. Abrahamsen JF, Stamnesfet S, Liseth K, Hervig T, Bruserud O. Large-volume leukapheresis yields more viable CD34+ cells and colony-forming units than normal-volume leukapheresis, especially in patients who mobilize low numbers of CD34+ cells. Transfusion 2005;45:248-253.
7. Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Gastineau DA, Litzow MR, Fonseca R, Roy V, Rajkumar SV, Gertz MA. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia 2007;21:2035-2042.
8. Sugrue MW, Williams K, Pollock BH, Khan S, Paracha S, Wingard JR, Moreb JS. Characterization and outcome of "hard to mobilize" lymphoma patients undergoing autologous stem cell transplantation. Leuk Lymphoma 2001;39:509-519.
9. Watts MJ, Ings SJ, Flynn M, Dodds D, Goldstone AH, Linch DC. Remobilization of patients who fail to achieve minimal progenitor thresholds at the first attempt is clinically worthwhile. Br J Haematol 2000;111:287-291.
10. Sohn SK, Kim JG, Chae YS, Kim DH, Lee NY, Suh JS, Lee KB. Large-volume leukapheresis using femoral venous access for harvesting peripheral blood stem cells with the Fenwal CS 3000 Plus from normal healthy donors: predictors of CD34+ cell yield and collection efficiency. J Clin Apher 2003;18:10-15.
11. Zubair AC, Grant R, Wu W, Tun H, Rivera C, Moreno-Aspitia A, Joyce M, Roy V, Colon-Otero G, Solberg LA. Platelet count is a sensitive predictor of autologous peripheral blood progenitor cell collection yield in previously treated plasma cell disease patients. Transfusion 2008;48:1106-1114.
12. Cottler-Fox M, Lapidot T. Mobilizing the older patient with myeloma. Blood Rev 2006;20:43-50.
13. Cottler-Fox MH, Lapidot T, Petit I, Kollet O, DiPersio JF, Link D, Devine S. Stem cell mobilization. Hematology (Am Soc Hematol Educ Program) 2003:419-437.
14. Gidron A, Singh V, Egan K, Mehta J. Significance of low peripheral blood CD34+ cell numbers prior to leukapheresis: what should the threshold required for apheresis be? Bone Marrow Transplant 2008;42:439-442.
15. Desikan KR, Jagannath S, Siegel D, Nelson J, Bracy D, Barlogie B, Tricot G. Collection of more hematopoietic progenitor cells with large volume leukapheresis in patients with multiple myeloma. Leuk Lymphoma 1998;28: 501-508.
16. Humpe A, Riggert J, Munzel U, Kohler M. A prospective, randomized, sequential crossover trial of large-volume versus normal-volume leukapheresis procedures: effects on serum electrolytes, platelet counts, and other coagulation measures. Transfusion 2000;40:368-374.
17. Reik RA, Noto TA, Fernandez HF. Safety of large-volume leukapheresis for collection of peripheral blood progenitor cells. J Clin Apher 1997;12:10-13.
18. Mcleod B, editor. Mobilization and Collection of Peripheral Blood Progenitor Cells. Apheresis: Principle and Practice. Bethesda, MD: AABB Press; 2003.
19. Bolan CD, Leitman SF. Management of anticoagulation-associated toxicity during large-volume leukapheresis of peripheral blood stem cell donors. Blood 2002;99:1878.
20. Bolan CD, Carter CS, Wesley RA, Yau YY, Barrett AJ, Childs RW, Read EJ, Leitman SF. Prospective evaluation of cell kinetics, yields and donor experiences during a single large-volume apheresis versus two smaller volume consecutive day collections of allogeneic peripheral blood stem cells. Br J Haematol 2003;120:801-807.
21. Bolan CD, Cecco SA, Wesley RA, Horne M, Yau YY, Remaley AT, Childs RW, Barrett AJ, Rehak NN, Leitman SF. Controlled study of citrate effects and response to i.v. calcium administration during allogeneic peripheral blood progenitor cell donation. Transfusion 2002;42:935-946.
22. Zubair A, Zahrieh D, Daley H, Schott D, Gribben JG, Freedman A, Ritz J. Early neutrophil engraftment following autologous BMT provides a functional predictor of long-term hematopoietic reconstitution. Transfusion 2003;43: 614-621.
23. Zubair AC, Zahrieh D, Daley H, Schott D, Gribben JG, Alyea EP, Schlossman R, Freedman A, Antin JH, Soiffer RJ, Neuberg D, Ritz J. Engraftment of autologous and allogeneic marrow HPCs after myeloablative therapy. Transfusion 2004;44:253-261.
24. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, Casassus P, Maisonneuve H, Facon T, Ifrah N, Payen C, Bataille R. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996;335:91-97.
25. Kroger N, Perez-Simon JA, Myint H, Klingemann H, Shimoni A, Nagler A, Martino R, Alegre A, Tomas JF, Schwerdtfeger R, Kiehl M, Fauser A, Sayer HG, Leon A, Beyer J, Zabelina T, Ayuk F, San Miguel JF, Brand R, Zander AR. Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/ fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma. Biol Blood Marrow Transplant 2004;10:698-708.